ClinicalTrials.gg
TerminatedNCT05579639Updated Nov 2, 2026

Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

A Phase 2 interventional study of Xylitol and Placebo in Allogeneic Stem Cell Transplantation, sponsored by Children's Hospital Medical Center, Cincinnati. Terminated at 3 sites in United States. Open to participants aged 4 Months to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 2, Interventional, and Prevention

How we know

Why this study was terminated
At the recommendation of the DSMB, the study was halted following an interim futility analysis, which determined that continued enrollment would not alter the study outcome.
Updated Nov 2, 2026Now TerminatedStudy documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
4 Months to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 517 studies in Sepsis with a site in United States — 74 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.

Enrollment
97th of 310
256 · median 84
Started
2023
with 19 others
Phase 2
50 of 517
4 open now
Registered
422nd of 517
by date

Among the 517 studies in Sepsis with a site in United States, this one is the 97th largest by enrollment of the 310 interventional ones that give a count, is one of 20 that started in 2023, is one of 50 in phase 2, and was the 422nd registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

74 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 4 Months to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 517 studies in Sepsis with a site in United States, or all of them as a file.
02

Study summary

Bloodstream infections (BSI) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (SCT). Unfortunately, there are currently no known strategies to prevent these BSI in this vulnerable population. The investigators will conduct a randomized, double-blind, placebo-controlled trial at three institutions to evaluate the effectiveness of twice daily intraoral xylitol-wipe application on reducing BSI in pediatric SCT patients.

Read the detailed description

Patients will be randomized to receive either twice-daily intraoral grape-flavored xylitol-wipe (intervention arm) or grape-flavored saline wipe (control arm) application in addition to the current standard of care (SOC). The purpose of this study is to determine whether xylitol wipes are effective at reducing bloodstream infections (BSIs), dental plaque, mucositis (redness and ulcers in the mouth), or gingivitis in patients who undergo allogeneic stem cell transplant (SCT).

03

Conditions studied

  • Allogeneic Stem Cell Transplantation

Keywords

  • bloodstream infections
  • oral health
  • xylitol
  • dental health
  • gingivitis
  • mucositis
  • plaque
04

Who can participate

Ages eligible
4 Months to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide signed and dated and assent (when applicable) form
  • Willing to comply with all study procedures and be available for the duration of the study
  • Admitted and planning to undergo an stem cell transplant (SCT) at Cincinnati Children's Hospital Medical Center (CCHMC), Boston Children's Hospital, or Children's Hospital of Colorado (Denver).
  • Male or female, 4 months to 25 years of age at the time of SCT (Day 0)
  • Have a minimum of one tooth
  • Agree to avoid chewing gum and toothpaste that contains xylitol during the intervention period

Exclusion criteria

Exclusion Criteria:

  • Prior radiation treatment for cancer of the oral cavity, head, or neck in the past 6 months per the study participant's medical record
  • Cranial boost in patients receiving total body irradiation
  • Known history of allergy to xylitol
  • Known history of allergy to grapes or grape flavoring
  • Undergoing a conditioning-free stem cell transplant (patient does not receive any chemotherapy or radiation prior to stem cell infusion)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    Xylitol

    Xylitol, a naturally occurring sugar alcohol found in plums, strawberries, and various vegetables such as cauliflower, has been approved for use in food by the US FDA since 1963. Spiffies Xylitol Wipes will be used.

    Other: Xylitol

  • Placebo comparator
    Grape-flavored Wipes

    Grape-flavored wipes will be used with 2 drops of PCCA colorless grape flavoring. The grape-flavored wipes each contain a solution of 0.9% Sodium Chloride, purified water, and Benzalkonium chloride. PCCA artificial colorless grape flavoring will be used. The PCCA grape flavoring contains propylene glycol, ethyl alcohol, and artificial flavoring.

    Other: Placebo

Interventions

  • OtherXylitol

    Xylitol wipes

    Also known as: Spiffies Xylitol Wipes

  • OtherPlacebo

    Placebo wipes

    Also known as: Grape-Flavored Wipes

06

What researchers measure

Primary outcomes

  1. Bacteremia from an oral organism

    Incidence of bloodstream infection (BSI) from oral flora organisms in in patients receiving xylitol compared to placebo

    Time frame: 33 days

Secondary outcomes

  1. Bacteremia from other non-oral flora organisms

    Incidence of BSI from non-oral flora organisms in patients receiving xylitol compared to placebo

    Time frame: 33 days

  2. Dental plaque

    Debris Index Simplified (DI-S) score

    Time frame: 33 days

  3. Gingivitis

    Mean Modified Gingival Index (MGI) score

    Time frame: 33 days

  4. Objective mucositis

    Mean Oral Mucositis Assessment Scale (OMAS) score

    Time frame: 33 days

  5. Patient-reported mucositis

    ChIMES total score

    Time frame: 33 days

  6. Oral microbiome diversity

    Shannon Diversity Index

    Time frame: 33 days

07

Study locations

3 sites
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Dana-Farber/Boston Children's
    Boston, Massachusetts 02115, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Sep 2026, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2022
First posted
Oct 14, 2022
StartActual
Apr 4, 2023
Primary completionActual
Sep 11, 2026
CompletionActual
Sep 11, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated At the recommendation of the DSMB, the study was halted following an interim futility analysis, which determined that continued enrollment would not alter the study outcome.
changed Sep 28, 2026
Documents
Show all 2 updates
  1. Nov 2, 2026
    + 1 other change: verification date
  2. Sep 28, 2026
    Active, not recruiting→Terminated
    Why stopped At the recommendation of the DSMB, the study was halted following an interim futility analysis, which determined that continued enrollment would not alter the study outcome.
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05579639
Responsible party
Sponsor
First posted
Oct 14, 2022
Start date
Apr 4, 2023
Primary completion
Sep 11, 2026
Completion
Sep 11, 2026
Last update
Nov 2, 2026

Study contacts

Christopher Dandoy, MD, MSc
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion